VNRX

SEC source: 0001477932-22-007691 · form4.xml · nonDerivative · entry 1

Faulkes Martin Charles · CIK 0001577872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,582,068

F1 · shares: On October 4, 2022, the reporting person was awarded 39,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 6,825 restricted stock units vesting. The restricted stock units are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 2,275 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001477932-22-007690 · form4.xml · nonDerivative · entry 1

Nguyen Kim · CIK 0001852492 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,811

F1 · shares: On October 4, 2022, the reporting person was awarded 15,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 2,625 restricted stock units vesting. The restricted stock units are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 875 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001477932-22-007487 · form4.xml · nonDerivative · entry 1

Reynolds Cameron John · CIK 0001340610 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,395,518

F1 · shares: On October 4, 2022, the reporting person was awarded 200,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of a closing stock price target above $5.00 per share of the Issuer's common stock for a minimum of ten consecutive trading days prior to October 4, 2025, and also subject to time-based vesting in a single installment six months after the timely achievement of the target, if at all. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001477932-22-007485 · form4.xml · nonDerivative · entry 1

Hughes Terig · CIK 0001841309 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,740

F1 · shares: On October 4, 2022, the reporting person was awarded 100,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of a closing stock price target above $5.00 per share of the Issuer's common stock for a minimum of ten consecutive trading days prior to October 4, 2025, and also subject to time-based vesting in a single installment six months after the timely achievement of the target, if at all. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001477932-22-007486 · form4.xml · nonDerivative · entry 1

Faulkes Martin Charles · CIK 0001577872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,575,243

F1 · shares: On October 4, 2022, the reporting person was awarded 50,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of a closing stock price target above $5.00 per share of the Issuer's common stock for a minimum of ten consecutive trading days prior to October 4, 2025, and also subject to time-based vesting in a single installment six months after the timely achievement of the target, if at all. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001477932-22-007484 · form4.xml · nonDerivative · entry 2

Michel Gaetan · CIK 0001709503 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,997

F2 · shares: On October 4, 2022, the reporting person was awarded 100,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of a closing stock price target above $5.00 per share of the Issuer's common stock for a minimum of ten consecutive trading days prior to October 4, 2025, and also subject to time-based vesting in a single installment six months after the timely achievement of the target, if at all. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested

SEC source: 0001477932-22-007484 · form4.xml · nonDerivative · entry 1

Michel Gaetan · CIK 0001709503 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,997

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 19,905 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-22-007051 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 35,000

SEC source: 0001477932-22-006512 · form4.xml · nonDerivative · entry 1

Reynolds Cameron John · CIK 0001340610 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,195,518

SEC source: 0001477932-22-006505 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 149,228

SEC source: 0001477932-22-006435 · form4.xml · nonDerivative · entry 1

Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 165,000

SEC source: 0001477932-22-006406 · form4.xml · nonDerivative · entry 1

Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,000

SEC source: 0001477932-22-006199 · form4.xml · nonDerivative · entry 1

Henshall Mickie · CIK 0001939342 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

F1 · shares: Ms. Henshall received restricted stock units subject to a 2-year vesting schedule, vesting as to 7,500 units on each of 08/15/23 and 08/15/24, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001477932-22-005692 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,228

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 12,063 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction

SEC source: 0001477932-22-005690 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commerical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,375

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 10,237 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-22-005691 · form4.xml · nonDerivative · entry 1

Faulkes Martin Charles · CIK 0001577872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,525,243

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 12,063 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-22-005689 · form4.xml · nonDerivative · entry 2

TERRELL JASON BRADLEY MD · CIK 0001567531 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 2,326

F2 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the spouse of the reporting person upon settlement of 1,365 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-22-005689 · form4.xml · nonDerivative · entry 1

TERRELL JASON BRADLEY MD · CIK 0001567531 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,866

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 17,573 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-22-005632 · form4.xml · nonDerivative · entry 5

Innes Guy Archibald · CIK 0001579377 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By daughter

Disclosed balance after: 75,000

F2 · shares: Acquired by the reporting person's child at the public offering price in the public offering of common stock by the Company. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

F2 · ownership.nature: Acquired by the reporting person's child at the public offering price in the public offering of common stock by the Company. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

SEC source: 0001477932-22-005632 · form4.xml · nonDerivative · entry 4

Innes Guy Archibald · CIK 0001579377 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By daughter

Disclosed balance after: 75,000

F2 · shares: Acquired by the reporting person's child at the public offering price in the public offering of common stock by the Company. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

F2 · ownership.nature: Acquired by the reporting person's child at the public offering price in the public offering of common stock by the Company. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

SEC source: 0001477932-22-005632 · form4.xml · nonDerivative · entry 3

Innes Guy Archibald · CIK 0001579377 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By son

Disclosed balance after: 75,000

F2 · shares: Acquired by the reporting person's child at the public offering price in the public offering of common stock by the Company. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

F2 · ownership.nature: Acquired by the reporting person's child at the public offering price in the public offering of common stock by the Company. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

SEC source: 0001477932-22-005632 · form4.xml · nonDerivative · entry 2

Innes Guy Archibald · CIK 0001579377 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By son

Disclosed balance after: 75,000

F2 · shares: Acquired by the reporting person's child at the public offering price in the public offering of common stock by the Company. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

F2 · ownership.nature: Acquired by the reporting person's child at the public offering price in the public offering of common stock by the Company. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

SEC source: 0001477932-22-005632 · form4.xml · nonDerivative · entry 1

Innes Guy Archibald · CIK 0001579377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,562,161

F1 · shares: Acquired at the public offering price in the public offering of common stock by the Company.

SEC source: 0001477932-22-004666 · form4.xml · derivative · entry 2

Brudnick Richard · CIK 0001692359 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,635

Underlying: Common Stock · 5,613 shares

Expires 2031-08-03

F2 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 8,635 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 5,613 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 2,807 shares and 2,806 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 3,022 shares subject to the award previously vested and remain subject to time-based vesting.

F2 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 8,635 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 5,613 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 2,807 shares and 2,806 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 3,022 shares subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-004666 · form4.xml · nonDerivative · entry 1

Brudnick Richard · CIK 0001692359 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,686

F1 · shares: On August 3, 2021, the reporting person was awarded 4,686 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 3,046 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two equal installments of 1,523 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in April 2022, the rights with respect to the remaining 1,640 restricted stock units subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-004667 · form4.xml · derivative · entry 1

Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,400

Underlying: Common Stock · 34,060 shares

Expires 2031-08-03

F1 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 52,400 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 34,060 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 17,030 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 18,340 shares subject to the award previously vested and remain subject to time-based vesting.

F1 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 52,400 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 34,060 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 17,030 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 18,340 shares subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-004665 · form4.xml · derivative · entry 3

Nguyen Kim · CIK 0001852492 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,635

Underlying: Common Stock · 5,613 shares

Expires 2031-08-03

F2 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 8,635 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 5,613 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 2,807 shares and 2,806 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 3,022 shares subject to the award previously vested and remain subject to time-based vesting.

F2 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 8,635 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 5,613 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 2,807 shares and 2,806 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 3,022 shares subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-004665 · form4.xml · nonDerivative · entry 1

Nguyen Kim · CIK 0001852492 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,186

F1 · shares: On August 3, 2021, the reporting person was awarded 4,686 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 3,046 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two equal installments of 1,523 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in April 2022, the rights with respect to the remaining 1,640 restricted stock units subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-004664 · form4.xml · derivative · entry 3

Futcher Edward · CIK 0001222623 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,653

Underlying: Common Stock · 5,613 shares

Expires 2031-08-03

F3 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 8,635 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 5,613 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 2,807 shares and 2,806 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 3,022 shares subject to the award previously vested and remain subject to time-based vesting.

F3 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 8,635 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 5,613 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 2,807 shares and 2,806 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 3,022 shares subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-004664 · form4.xml · nonDerivative · entry 1

Futcher Edward · CIK 0001222623 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,936

F1 · shares: On August 3, 2021, the reporting person was awarded 4,686 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 3,046 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two equal installments of 1,523 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in April 2022, the rights with respect to the remaining 1,640 restricted stock units subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-004663 · form4.xml · derivative · entry 4

Innes Guy Archibald · CIK 0001579377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,635

Underlying: Common Stock · 5,613 shares

Expires 2031-08-03

F4 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 8,635 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 5,613 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 2,807 shares and 2,806 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 3,022 shares subject to the award previously vested and remain subject to time-based vesting.

F4 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 8,635 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 5,613 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 2,807 shares and 2,806 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 3,022 shares subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-004663 · form4.xml · nonDerivative · entry 1

Innes Guy Archibald · CIK 0001579377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,549,661

F1 · shares: On August 3, 2021, the reporting person was awarded 4,686 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 3,046 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two equal installments of 1,523 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in April 2022, the rights with respect to the remaining 1,640 restricted stock units subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-004662 · form4.xml · derivative · entry 4

Reynolds Cameron John · CIK 0001340610 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,486

Underlying: Common Stock · 59,466 shares

Expires 2031-08-03

F3 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 91,486 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 59,466 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 29,733 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 32,020 shares subject to the award previously vested and remain subject to time-based vesting.

F3 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 91,486 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 59,466 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 29,733 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 32,020 shares subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-004662 · form4.xml · nonDerivative · entry 1

Reynolds Cameron John · CIK 0001340610 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,192,018

F1 · shares: On August 3, 2021, the reporting person was awarded 49,645 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 32,270 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 16,136 units and 16,134 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in April 2022, the rights with respect to the remaining 17,375 restricted stock units subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-004661 · form4.xml · derivative · entry 4

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,457

Underlying: Common Stock · 28,898 shares

Expires 2031-08-03

F3 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 44,457 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 28,898 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 14,450 shares and 14,448 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 15,559 shares subject to the award previously vested and remain subject to time-based vesting.

F3 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 44,457 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 28,898 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 14,450 shares and 14,448 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 15,559 shares subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-004661 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,053

F1 · shares: On August 3, 2021, the reporting person was awarded 24,125 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 15,682 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 7,842 units and 7,840 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in April 2022, the rights with respect to the remaining 8,443 restricted stock units subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-004660 · form4.xml · derivative · entry 2

Michel Gaetan · CIK 0001709503 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,360

Underlying: Common Stock · 47,684 shares

Expires 2031-10-04

F2 · derivative.exercise_date: On October 4, 2021, the reporting person was granted an option to purchase 73,360 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 47,684 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 23,842 shares on each of October 4, 2022 and October 4, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 25,676 shares subject to the award previously vested and remain subject to time-based vesting.

F2 · balance_after: On October 4, 2021, the reporting person was granted an option to purchase 73,360 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 47,684 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 23,842 shares on each of October 4, 2022 and October 4, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 25,676 shares subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-004660 · form4.xml · nonDerivative · entry 1

Michel Gaetan · CIK 0001709503 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,880

F1 · shares: On October 4, 2021, the reporting person was awarded 39,809 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 25,876 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 12,939 units and 12,937 units on each of October 4, 2022 and October 4, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in April 2022, the rights with respect to the remaining 13,933 restricted stock units subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-004659 · form4.xml · derivative · entry 2

Barnes Phillip · CIK 0001790293 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,635

Underlying: Common Stock · 5,613 shares

Expires 2031-08-03

F2 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 8,635 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 5,613 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 2,807 shares and 2,806 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 3,022 shares subject to the award previously vested and remain subject to time-based vesting.

F2 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 8,635 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 5,613 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 2,807 shares and 2,806 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 3,022 shares subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-004659 · form4.xml · nonDerivative · entry 1

Barnes Phillip · CIK 0001790293 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,686

F1 · shares: On August 3, 2021, the reporting person was awarded 4,686 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 3,046 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two equal installments of 1,523 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in April 2022, the rights with respect to the remaining 1,640 restricted stock units subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-004658 · form4.xml · derivative · entry 3

Kway Jasmine · CIK 0001808135 · CEO - Singapore Volition

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,567

Underlying: Common Stock · 32,869 shares

Expires 2031-08-03

F2 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 50,567 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 32,869 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 16,435 shares and 16,434 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 17,698 shares subject to the award previously vested and remain subject to time-based vesting.

F2 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 50,567 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 32,869 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 16,435 shares and 16,434 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 17,698 shares subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-004658 · form4.xml · nonDerivative · entry 1

Kway Jasmine · CIK 0001808135 · CEO - Singapore Volition

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,440

F1 · shares: On August 3, 2021, the reporting person was awarded 27,440 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 17,836 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two equal installments of 8,918 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in April 2022, the rights with respect to the remaining 9,604 restricted stock units subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-004657 · form4.xml · derivative · entry 4

Forterre Gael · CIK 0001841637 · Chief Commerical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,728

Underlying: Common Stock · 24,524 shares

Expires 2031-08-03

F3 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 37,728 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 24,524 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 12,262 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 13,204 shares subject to the award previously vested and remain subject to time-based vesting.

F3 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 37,728 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 24,524 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 12,262 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 13,204 shares subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-004657 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commerical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,973

F1 · shares: On August 3, 2021, the reporting person was awarded 20,473 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 13,308 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 6,655 units and 6,653 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in April 2022, the rights with respect to the remaining 7,165 restricted stock units subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-004655 · form4.xml · derivative · entry 3

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,050

Underlying: Common Stock · 24,083 shares

Expires 2031-08-03

F3 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 37,050 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 24,083 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 12,042 shares and 12,041 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 12,967 shares subject to the award previously vested and remain subject to time-based vesting.

F3 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 37,050 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 24,083 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 12,042 shares and 12,041 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 12,967 shares subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-004655 · form4.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,502

F1 · shares: On August 3, 2021, the reporting person was awarded 20,104 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 13,068 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two equal installments of 6,534 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in April 2022, the rights with respect to the remaining 7,036 restricted stock units subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-004656 · form4.xml · derivative · entry 4

TERRELL JASON BRADLEY MD · CIK 0001567531 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 5,030

Underlying: Common Stock · 3,270 shares

Expires 2031-08-03

F4 · derivative.exercise_date: On August 3, 2021, the spouse of the reporting person was granted an option to purchase 5,030 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 3,270 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 1,635 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 1,760 shares subject to the award previously vested and remain subject to time-based vesting.

F4 · balance_after: On August 3, 2021, the spouse of the reporting person was granted an option to purchase 5,030 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 3,270 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 1,635 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 1,760 shares subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-004656 · form4.xml · derivative · entry 3

TERRELL JASON BRADLEY MD · CIK 0001567531 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,766

Underlying: Common Stock · 42,098 shares

Expires 2031-08-03

F3 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 64,766 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 42,098 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 21,049 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 22,668 shares subject to the award previously vested and remain subject to time-based vesting.

F3 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 64,766 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 42,098 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 21,049 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 22,668 shares subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-004656 · form4.xml · nonDerivative · entry 2

TERRELL JASON BRADLEY MD · CIK 0001567531 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 2,730

F2 · shares: On August 3, 2021, the spouse of the reporting person was awarded 2,730 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect 1,775 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 888 units and 887 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in April 2022, the rights with respect to the remaining 955 restricted stock units subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-004656 · form4.xml · nonDerivative · entry 1

TERRELL JASON BRADLEY MD · CIK 0001567531 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,145

F1 · shares: On August 3, 2021, the reporting person was awarded 35,145 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect 22,845 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 11,423 units and 11,422 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in April 2022, the rights with respect to the remaining 12,300 restricted stock units subject to the award previously vested and remain subject to time-based vesting.